Literature DB >> 20045200

Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis.

Orhan Aktas1, Bernd Kieseier, Hans-Peter Hartung.   

Abstract

Multiple sclerosis (MS), an incurable but manageable disorder, is characterized by chronic inflammatory demyelination and neurodegeneration in the central nervous system. Although the primary cause of this often devastating disease remains elusive, major therapeutic advances have occurred during the past two decades. Here, we present a review of current immunomodulatory treatments and outline upcoming therapy approaches, including biologics and oral alternatives that might have equivalent or superior efficacy and/or enhanced tolerability compared with available treatments, and discuss the scientific rationale and expected benefits and risks for these compounds. We also speculate about alternatives beyond immune-directed approaches, review novel insights into the neurobiological consequences of sustained brain inflammation and evaluate future perspectives for neuroprotective and neuroregenerative treatment strategies for MS. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20045200     DOI: 10.1016/j.tins.2009.12.002

Source DB:  PubMed          Journal:  Trends Neurosci        ISSN: 0166-2236            Impact factor:   13.837


  30 in total

Review 1.  Immune mediated diseases and immune modulation in the neurocritical care unit.

Authors:  Gloria von Geldern; Thomas McPharlin; Kyra Becker
Journal:  Neurotherapeutics       Date:  2012-01       Impact factor: 7.620

2.  Effect of Fingolimod on Neural Stem Cells: A Novel Mechanism and Broadened Application for Neural Repair.

Authors:  Yuan Zhang; Xing Li; Bogoljub Ciric; Cun-Gen Ma; Bruno Gran; Abdolmohamad Rostami; Guang-Xian Zhang
Journal:  Mol Ther       Date:  2016-12-28       Impact factor: 11.454

3.  [Immunotherapy and infectious issues in multiple sclerosis. Self-injectable and oral drugs for immunotherapy].

Authors:  A Winkelmann; M Löbermann; E C Reisinger; H-P Hartung; U K Zettl
Journal:  Nervenarzt       Date:  2015-08       Impact factor: 1.214

Review 4.  Treatment update in multiple sclerosis.

Authors:  Katrina Morris; Con Yiannikas
Journal:  Curr Allergy Asthma Rep       Date:  2012-06       Impact factor: 4.806

Review 5.  Disease-modifying therapies and infectious risks in multiple sclerosis.

Authors:  Alexander Winkelmann; Micha Loebermann; Emil C Reisinger; Hans-Peter Hartung; Uwe K Zettl
Journal:  Nat Rev Neurol       Date:  2016-03-04       Impact factor: 42.937

Review 6.  Promoting myelin repair and return of function in multiple sclerosis.

Authors:  Jingya Zhang; Elisabeth G Kramer; Linnea Asp; Dipankar J Dutta; Kristina Navrazhina; Trinh Pham; John N Mariani; Azeb Tadesse Argaw; Carmen V Melendez-Vasquez; Gareth R John
Journal:  FEBS Lett       Date:  2011-08-18       Impact factor: 4.124

Review 7.  The therapeutic potential of HDAC inhibitors in the treatment of multiple sclerosis.

Authors:  Giuseppe Faraco; Leonardo Cavone; Alberto Chiarugi
Journal:  Mol Med       Date:  2011-02-25       Impact factor: 6.354

8.  Pathologic heterogeneity persists in early active multiple sclerosis lesions.

Authors:  Imke Metz; Stephen D Weigand; Bogdan F G Popescu; Josa M Frischer; Joseph E Parisi; Yong Guo; Hans Lassmann; Wolfgang Brück; Claudia F Lucchinetti
Journal:  Ann Neurol       Date:  2014-05-13       Impact factor: 10.422

9.  Green tea epigallocatechin-3-gallate modulates differentiation of naïve CD4⁺ T cells into specific lineage effector cells.

Authors:  Junpeng Wang; Munkyong Pae; Simin Nikbin Meydani; Dayong Wu
Journal:  J Mol Med (Berl)       Date:  2012-10-12       Impact factor: 4.599

10.  [Fingolimod compassionate use program: case study on the concept of a therapy option for multiple sclerosis prior to marketing approval].

Authors:  J Haas; R A Linker; H P Hartung; M Meergans; S Ortler; F Tracik
Journal:  Nervenarzt       Date:  2012-12       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.